Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Regeneron Pharmaceuticals is conducting a clinical study titled A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity. The study aims to evaluate the safety and effectiveness of trevogrumab, with or without garetosmab, combined with semaglutide in promoting weight loss, fat loss, and lean mass preservation in adults with obesity. This research is significant as it explores potential new treatments for obesity, a growing global health concern.
The study tests the experimental drugs trevogrumab and garetosmab, alongside semaglutide (Wegovy®). Trevogrumab and garetosmab are administered to assess their safety and efficacy in combination with semaglutide, which is already used for weight management.
This interventional study is randomized and follows a sequential intervention model with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are blinded. The primary purpose of the study is treatment-focused.
The study began on March 13, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 14, 2025, indicating ongoing progress.
The outcome of this study could influence Regeneron’s stock performance and investor sentiment, as successful results may enhance the company’s portfolio in the obesity treatment market. This could also impact competitors in the pharmaceutical industry focusing on obesity treatments.
The study is currently ongoing, with further details available on the ClinicalTrials portal.